20 articles
A Phase 2 trial investigates whether thiethylperazine, a decades-old antiemetic, can flush toxic amyloid beta from the brains of early AD patients.
A Phase 1/2 trial tests whether dexmedetomidine can enhance the brain's glymphatic system to clear amyloid and tau during sleep.
A Phase 1 trial examines how gadobutrol moves through and exits the bodies of newborns and toddlers undergoing routine contrast MRI.
A completed trial tests EGCG combined with diet, exercise, and cognitive training to slow decline in ApoE4 carriers with early warning signs.
Small doses of psilocybin tested against placebo in 39 adults with major depressive disorder to assess safety and mood benefits.
Small study tests psychedelic compound's safety and effectiveness against severe depression that doesn't respond to standard treatments.
A completed trial tests whether daily Nordic berry beverages can sharpen cognition in healthy adults over 12 weeks.
Clinical trial explores how targeted light treatment could restore circadian rhythms and improve brain function in mild cognitive impairment.
A double-blind trial tests whether 810nm photobiomodulation can reverse cognitive impairment in long COVID patients at home.
A completed University of Kansas trial investigates whether creatine monohydrate can support brain energy metabolism in Alzheimer's patients.
Completed French trial uses advanced brain imaging to track 5-HT4 serotonin receptors in Parkinson's patients, linking genetics to cognitive and mood changes.
The EPICURO trial tests MERIVA® turmeric over 6 months to see if it protects cognition in adults with metabolic syndrome.
Phase 1b trial tests escalating doses of experimental Alzheimer's treatment BMS-984923 for safety and tolerability in older adults.
Researchers at Duke University tested a blood-based biomarker to stratify Alzheimer's patients from healthy adults, aiming to enable earlier detection.
French researchers followed 1,028 people with mild cognitive complaints to understand how dementia develops over time.
A pilot trial tests whether group and phone-based CBT can sharpen cognition and cut chronic stress in African Americans at risk for Alzheimer's.
A Phase 2 trial explores whether cilostazol, a blood thinner with brain-protective effects, can slow memory loss in MCI patients.
60-person study tested psilocybin alone and with CBT for major depression, measuring brain activity and inflammatory markers.
Combining Mediterranean-DASH diet with nature therapy targets hypertension and cognitive decline in older adults.
Duke University study tests whether targeted brain stimulation can reverse age-related cognitive decline and improve working memory.
